540729 — Vanta Bioscience Income Statement
0.000.00%
- IN₹131.04m
- IN₹744.74m
- IN₹97.23m
Annual income statement for Vanta Bioscience, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 141 | 100 | 96.9 | 62.8 | 97.2 |
Cost of Revenue | |||||
Gross Profit | 130 | 92.2 | 89.9 | 53.3 | 90 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 110 | 72.9 | 75.4 | 113 | 129 |
Operating Profit | 31.8 | 27.5 | 21.5 | -50.6 | -31.8 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 13.4 | 5.89 | 2.28 | -103 | -88.3 |
Provision for Income Taxes | |||||
Net Income After Taxes | 10.1 | 4.48 | 1.35 | -104 | -86.1 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 10 | 4.5 | 0.882 | -64.8 | -23.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 10 | 4.5 | 0.882 | -64.8 | -23.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.59 | 0.686 | 0.14 | -10.3 | -3.67 |